We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. It focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally-invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia. PROCEPT BioRobotics Corporation is based in REDWOOD CITY, Calif.
- Recent PRCT Stock Price: $31.29
- Yearly Gain for PRCT stock: -18.06%
- Market Cap for PRCT stock: $1.36B
- P/E Ratio for PRCT stock: -13.809
Will PRCT's stock price go up? Is there an accurate PRCT stock forecast available?
TipRanks.com reports that PROCEPT BioRobotics currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $47.80. The target pricing ranges from a high PRCT forecast of $60.00 down to a low forecast of $39.00. PROCEPT BioRobotics (PRCT)’s last closing stock price was $31.29 which would put the average price target at 52.76% upside.
In addition, TradingView issued a Strong Sell rating for PRCT stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on PRCT stock.
Other analysts covering PRCT include:
- Neil Chatterji of B.Riley Financial issued a Buy rating with the price target of $ 60 on 20 hours ago
- Richard Newitter of Truist Financial issued a Buy rating with the price target of $ 49 on 3 days ago
- Nathan Treybeck of Wells Fargo issued a Buy rating with the price target of $ 39 on 3 days ago
If you are wondering if PRCT is a good stock to buy, here are 3rd party ratings for PRCT stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Sell, Top 44% (110 out of 251)
What is the sentiment on the street regarding PROCEPT BioRobotics? (Current ratings compiled by TipRanks.com)
- News Sentiment for PRCT stock: Bullish
- Blogger Consensus for PRCT stock: Bullish
- Media Buzz for PRCT stock: Very High
- Insider Signal for PRCT stock: Negative
- Investor Sentiment for PRCT stock: ―
- Hedge Fund signal for PRCT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on PRCT stock including scouring the social networks like PRCT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PRCT stock chart >>
Summary: AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
- Recent ABBV Stock Price: $153.71
- Yearly Gain for ABBV stock: 6.16%
- Market Cap for ABBV stock: $267.39B
- P/E Ratio for ABBV stock: 35.533
Will ABBV's stock price go up? Is there an accurate ABBV stock forecast available?
TipRanks.com reports that AbbVie currently has 16 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $162.79. The target pricing ranges from a high ABBV forecast of $195.00 down to a low forecast of $133.00. AbbVie (ABBV)’s last closing stock price was $153.71 which would put the average price target at 5.91% upside.
In addition, TradingView issued a Sell rating for ABBV stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ABBV stock.
Other analysts covering ABBV include:
- Unknown Analyst of Barclays issued a Hold rating with the price target of $ 160 on 20 hours ago
- David Risinger of SVB Securities issued a Hold rating with the price target of $ 153 on 1 day ago
- Chris Shibutani of Goldman Sachs issued a Hold rating with the price target of $ 141 on 3 days ago
- Terence Flynn of Morgan Stanley issued a Buy rating with the price target of $ 182 on 3 days ago
If you are wondering if ABBV is a good stock to buy, here are 3rd party ratings for ABBV stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 24% (59 out of 251)
What is the sentiment on the street regarding AbbVie? (Current ratings compiled by TipRanks.com)
- News Sentiment for ABBV stock: Bullish
- Blogger Consensus for ABBV stock: Bullish
- Media Buzz for ABBV stock: Very High
- Insider Signal for ABBV stock: Negative
- Investor Sentiment for ABBV stock: Neutral
- Hedge Fund signal for ABBV stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on ABBV stock including scouring the social networks like ABBV StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ABBV stock chart >>
Summary: PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.
- Recent PTCT Stock Price: $55.17
- Yearly Gain for PTCT stock: 52.40%
- Market Cap for PTCT stock: $4.09B
- P/E Ratio for PTCT stock: -6.985
Will PTCT's stock price go up? Is there an accurate PTCT stock forecast available?
TipRanks.com reports that PTC Therapeutics currently has 13 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $52.00. The target pricing ranges from a high PTCT forecast of $67.00 down to a low forecast of $35.00. PTC Therapeutics (PTCT)’s last closing stock price was $55.17 which would put the average price target at -5.75% upside.
In addition, TradingView issued a Buy rating for PTCT stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on PTCT stock.
Other analysts covering PTCT include:
- Brian Abrahams of RBC Capital issued a Hold rating with the price target of $ 52 on 3 days ago
- David Lebovitz of Citigroup issued a Buy rating with the price target of $ 67 on 3 days ago
- Judah Frommer of Credit Suisse issued a Hold rating with the price target of $ 51 on 3 days ago
- Joseph Schwartz of SVB Securities issued a Hold rating with the price target of $ 48 on 3 days ago
If you are wondering if PTCT is a good stock to buy, here are 3rd party ratings for PTCT stock:
- TipRanks.com: Hold
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 40% (100 out of 251)
What is the sentiment on the street regarding PTC Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for PTCT stock: Very Bullish
- Blogger Consensus for PTCT stock: ―
- Media Buzz for PTCT stock: Medium
- Insider Signal for PTCT stock: Very Negative
- Investor Sentiment for PTCT stock: ―
- Hedge Fund signal for PTCT stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on PTCT stock including scouring the social networks like PTCT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for PTCT stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
